Citigroup Downgrades Smith & Nephew (LON:SN) to Buy

Smith & Nephew (LON:SN) was downgraded by research analysts at Citigroup to a “buy” rating in a research note issued to investors on Friday,London Stock Exchange reports.

A number of other analysts have also recently weighed in on SN. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a GBX 1,350 price target on shares of Smith & Nephew in a research report on Monday, June 29th. Berenberg Bank restated a “hold” rating and issued a GBX 13 price target on shares of Smith & Nephew in a report on Friday, May 1st. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,760 price objective on shares of Smith & Nephew in a research report on Thursday, May 21st. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a GBX 1,400 price objective on shares of Smith & Nephew in a research note on Thursday, June 11th. Finally, UBS Group reissued a “neutral” rating and set a GBX 1,300 target price on shares of Smith & Nephew in a research report on Tuesday, May 5th. Three analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of GBX 1,382.62.

Smith & Nephew Price Performance

Smith & Nephew stock opened at GBX 1,130.50 on Friday. The stock has a market cap of £12.39 billion, a P/E ratio of 40.70, a price-to-earnings-growth ratio of 0.46 and a beta of 0.68. The company has a current ratio of 2.57, a quick ratio of 0.84 and a debt-to-equity ratio of 62.90. The stock has a 50 day moving average price of GBX 1,126.29 and a 200-day moving average price of GBX 1,204.99.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.